ADMA
ADMA Biologics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.62
+0.42%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
11.9x
EV/EBITDA
9.5x
Market Cap
$2.15B
MomentumView details →
1D Return
+0.42%
YTD Return
−47.64%
RSI (14)
53.3
ValuationView details →
P/E (Fwd)
11.9x
EV/EBITDA
9.5x
Market Cap
$2.15B
RSI (14)
53.3
MomentumView details →
1D Return
+0.42%
YTD Return
−47.64%
SummaryUpdated Jun 1, 2026
ADMA Biologics, Inc. (NASDAQ:ADMA) is a biopharmaceutical company founded in 2004 and headquartered in Ramsey, New Jersey. The company went public in 2013 and has evolved from a development-stage biotechnology firm into a profitable manufacturer of specialty plasma-derived biologics. ADMA operates as the last remaining 100% U.S.-domiciled plasma therapeutics company, maintaining a vertically integrated supply chain from plasma collection through manufacturing and distribution. The company has transformed significantly over the past few years, achieving profitability and substantial revenue growth driven primarily by its flagship product ASCENIV.
Similar companies
Latest newsMore news →
Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of ADMA Biologics, Inc.9d agoBank of America Corp DE increased its stake in ADMA Biologics Inc by 107.5% during the quarter, acquiring an additional 2,071,338 shares, according to a recent SEC filing.21d agoA securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. alleging misrepresentations about its financial condition and business practices.30d ago